{"analyses":[{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"1.17","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.28","pValueComment":"1-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Stratified log-rank test by performance status and histology.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.7","upperLimit":"13.5","value":"10"},{"groupId":"OG001","lowerLimit":"6.6","upperLimit":"13.8","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nCediranib Maleate: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG000","title":"Phase II Cisplatin-pemetrexed Cediranib 20mg"},{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG001","title":"Phase II Cisplatin-pemetrexed Placebo"}],"paramType":"MEDIAN","populationDescription":"Only eligible and analyzable patients are included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of registration to death.Disease assessment will be repeated every 6 weeks until disease progression. After progression, follow up will occur every 6 months for the first two years and then at the end of the third year after registration.","title":"Overall Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"month"}